Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 81

Results For "therapeutic"

1524 News Found

Syrma SGS acquires majority sake in Johari Digital Healthcare
Digitisation | August 02, 2023

Syrma SGS acquires majority sake in Johari Digital Healthcare

JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices


Concord Biotech’s IPO to open on 4th August, 2023
News | August 01, 2023

Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.


Biogen to acquire Reata Pharmaceuticals
News | July 31, 2023

Biogen to acquire Reata Pharmaceuticals

Proposed acquisition represents meaningful step forward in Biogen’s strategy for sustainable growth


Eugia Pharma receives USFDA approval for Plerixafor Injection
Drug Approval | July 26, 2023

Eugia Pharma receives USFDA approval for Plerixafor Injection

The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023


TransCure bioServices partners with Preclina to expands reach into APAC
Biotech | July 26, 2023

TransCure bioServices partners with Preclina to expands reach into APAC

Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders


Lupin receives approval from TGA Australia for Tiotropium Dry Powder
Drug Approval | July 26, 2023

Lupin receives approval from TGA Australia for Tiotropium Dry Powder

Tiotropium (as bromide monohydrate) 18 micrograms powder for inhalation in capsule


NATCO files generic Erdafitinib Tablets in USA
Drug Approval | July 26, 2023

NATCO files generic Erdafitinib Tablets in USA

Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma


Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs
Biotech | July 21, 2023

Riparian Pharmaceuticals inks license and research agreement with Pfizer for cardiovascular programs

Pfizer will make upfront and milestone payments, as well as pay royalties on sales of resulting therapeutics